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Abstract
Lubricin, encoded by the gene PRG4, is the principal lubricant in articulating joints. We im-
munized mice genetically deficient for lubricin (Prg4-/-) with purified human lubricin, and
generated several mAbs. We determined each mAb’s binding epitope, sensitivity, and spec-
ificity using biologic samples and recombinant lubricin sub-domains, and we also developed
a competition ELISA assay to measure lubricin in synovial fluid and blood. We found the
mAbs all recognized epitopes containing O-linked oligosaccharides conjugated to the pep-
tide motif KEPAPTTT. By western blot, the mAbs detected lubricin in 1 μl of synovial fluid
from several animal species, including human. The mAbs were specific for lubricin since
they did not cross-react with other synovial fluid constituents from patients with camptodac-
tyly-arthropathy-coxa vara-pericarditis syndrome (CACP), who genetically lack this protein.
The competition ELISA detected lubricin in blood samples from healthy individuals but not
from patients with CACP, indicating blood can be used in a diagnostic test for patients sus-
pected of having CACP. Lubricin epitopes in blood do not represent degradation fragments
from synovial fluid. Therefore, although blood lubricin levels did not differentiate patients
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with inflammatory joint disease from healthy controls, epitope-specific anti-lubricin mAbs
could be useful for monitoring disease activity in synovial fluid.
Introduction
Lubricin is a large (>250kDa), secreted, highly glycosylated mucinous protein that is abundant
in the synovial fluid of mammalian diarthrodal joints [1]. Lubricin is secreted by synovial fibro-
blasts [2] and superficial zone chondrocytes [3] as a monomer, dimer, or tetramer [4–6], and is
responsible for boundary lubrication [7–9] and the protection of articular cartilage from fric-
tion-induced damage [10]. Lubricin is also present on the surface of tendons and tendon
sheaths [11] and in the pericardial and pleural cavities, where it likely serves an anti-adhesive
function. Other tissues including liver, kidney, and skeletal muscle also express lubricin
mRNA, although the protein’s biologic role(s) in these tissues is unknown. In humans, genetic
absence of lubricin causes the camptodactyly-arthropathy-coxa vara-pericarditis syndrome
(CACP) [12,13]. Among the clinical consequences of CACP are non-inflammatory synovial
cell hyperplasia, precocious joint failure, adhesions between tendons and tendon sheaths, and
restrictive pericarditis [12]. Mice that have been genetically engineered to lack lubricin (Prg4-/-)
developed camptodactyly, synovial hyperplasia, and cartilage deterioration, similar to humans
with CACP [14–16]. Acquired deficiency of lubricin, due to enhanced degradation following
injury or inflammatory disease, may contribute to the deterioration of the involved joint [17];
in vitro studies have shown that reducing lubricin between loaded and sliding cartilage explants
leads to increases in the coefficient of friction and in chondrocyte apoptosis [18].
Full-length human lubricin is a 1404 amino acid residue protein encoded by the gene PRG4.
PRG4 gene products have also been identified as superficial zone protein (SZP), megakaryo-
cyte-stimulating factor (MSF) and hemangiopoietin (HAPO). The endogenous role for lubri-
cin/SZP at the cartilage surface is likely the same as for lubricin in synovial fluid, while HAPO
is a putative growth factor in the maturation of bone marrow hematopoietic cells [19]. In hu-
mans, more than half of the lubricin polypeptide contains 2 large mucin-like domains. The
first mucin domain contains multiple copies of the octapeptide motif KEPAPTTT. The threo-
nine residues in this motif are believed to be critical sites for O-linked sugar modifications
where β(1–3)Gal-GalNAc is incompletely capped with NeuAc [20]. Limited branching of O-
linked sugar chains has been observed in lubricin from patients with osteoarthritis (OA) and
rheumatoid arthritis (RA) [21]. The second mucin-like domain is also poly-threonine rich but
with a less recognizable motif structure. A hemopexin-like (PEX) domain at the carboxyl-ter-
minus of the protein likely confers specificity for matrix binding [22]. Proteolytic cleavage
within the PEX domain by subtilisin-like proprotein convertases has been observed [23].
Changes in lubricin abundance and intactness have been reported in animal joint injury
models and in humans with OA and RA. For example, lubricin abundance in synovial fluid de-
creased after cruciate ligament injury in rabbits [24] and humans [25]. In a rabbit model of RA
induced by methylated bovine serum albumin, decreased levels of synovial fluid lubricin were
also observed, and these decreases were due to decreased expression and increased proteolysis
[26]. Synovial fluid from patients with active RA and OA exhibited lubricin degradation [23].
Therefore, tools that permit sensitive and reproducible studies of lubricin quantity and quality
may be useful for understanding the role of this protein in maintaining joint health and predis-
posing to joint failure.
In order to better understand how lubricin is synthesized, post-translationally modified,
and degraded, we generated anti-human lubricin monoclonal antibodies (mAbs) in Prg4-/-
mice. We tested the mAbs on synovial fluid and blood samples from patients with CACP to
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show the mAbs are sensitive and specific for lubricin. We also showed that the mAbs recog-
nized lubricin from several other species. We delineated each mAb’s epitope and found that all
mAbs recognized an epitope with the same polypeptide motif; however, each mAb exhibited
different sensitivity to O-linked oligosaccharide post-translational modifications of this motif.
These new mAbs could detect lubricin by immunoblotting, immunoprecipitation, immunohis-
tology, and competition ELISA. Anti-lubricin mAbs with defined epitopes, sensitivities, and
specificities will be useful in diagnosing patients suspected of having CACP and in studying
lubricin in patients and animal models affected by joint disease.
Materials and Methods
The University Hospitals of Cleveland, the Rhode Island Hospital, the Brigham and Women’s
Hospital, and the Boston Children’s Hospital Institutional Review Boards approved this study.
Written informed consent and assent (for minors older than 8 years-of-age) were obtained by
Dr. Warman in the Division of Human Genetics at University Hospitals of Cleveland or the
Department of Orthopaedic Surgery at Boston Children’s Hospital from participants with
CACP, their unaffected siblings, and their carrier parents (n = 6). Written consent was not re-
quired, nor obtained, for fully anonymized samples that would otherwise have been discarded
following a clinical procedure. Anonymized blood samples from adult patients with rheuma-
toid arthritis and controls (n = 60) were provided by the Division of Rheumatology, Immunol-
ogy and Allergy, Brigham andWomen’s Hospital, Boston, MA. Anonymized adult synovial
fluid samples were provided by the Department of Orthopaedic Surgery at University Hospitals
of Cleveland, Cleveland OH and the Department of Emergency Medicine at Rhode Island Hos-
pital, Providence RI (n = 6). Anonymized synovial tissue sections from patients with degenera-
tive arthritis were obtained from the Department of Pathology, Boston Children’s Hospital,
Boston, MA (n = 4). The Institutional Animal Care and Use Committees at Case Western Re-
serve University, Cleveland, OH and Brown University, Providence, RI also approved these
studies. Cow, pig, and goat synovial fluid were obtained from a local abattoir. Dog, rat, and
guinea pig synovial fluid were obtained after euthanasia by exsanguination under deep anesthe-
sia. No animal was euthanized specifically for this study. Synovial fluid was collected from ani-
mals that had been euthanized under other IACUC approved protocols.
Generation and purification of anti-lubricin monoclonal antibodies
(mAbs)
Purified human lubricin was obtained as described [7]. Prg4-/- mice [14] were immunized with
lubricin mixed with complete Freund adjuvant using standard methods. Following sacrifice,
splenocytes were collected and hybridomas generated by fusion with SP2/0 cells. Hybridomas
were cultured in HAT-RPMI media for two weeks after which direct ELISA was performed to
test cell culture supernatants for the presence of anti-lubricin antibody. Positive hybridomas
were injected into the abdominal cavity of nude mice primed with pristane. Ascites fluid con-
taining high concentrations (1~2 mg/ml) of anti-lubricin antibody was collected. After centri-
fugation for 5 min to get rid of lipid and blood cell contamination, the ascites fluid was filtered
with a 0.8 μm filter and stored in -20°C until use or purification. Antibody was purified using
Protein G agarose beads.
Purified antibody was labeled with biotin using EZ-link Sulfo-NHS-LC-Biotin reagent
(Pierce, Rockford, IL). The antibody (0.2 mg/ml) was mixed with Sulfo-NHS-biotin reagent
(2 mM) at 4°C for 2 hr. Unreacted Sulfo-NHS-biotin was removed by dialysis in PBS buffer
at 4°C overnight. The concentration of the biotin-labeled antibody was determined by OD
readings at 280 nm wavelength.
Immunodetection of Lubricin
PLOS ONE | DOI:10.1371/journal.pone.0116237 February 2, 2015 3 / 17
Collection of synovial fluid and blood samples
Human synovial fluid was obtained following diagnostic aspiration of affected knees. Synovial
fluid samples were stored at -20°C. Plasma and/or serum samples were obtained from patients
with CACP, OA, RA and healthy controls. Plasma from patients and unaffected relatives with
CACP were stored at 4°C, while control and RA serum samples were stored at -20°C. Synovial
fluid aspirates from different species were collect immediately following euthanasia and stored
at -20°C.
Recombinant Human Lubricin (rhPRG4)
Full-length rhPRG4, comprising 1404 amino acids (GenBank: NP_005798), was expressed by
transformed Chinese hamster ovary cells (SBH Sciences, Natick, MA). This product appears as
a monomer and homodimer on agarose gel electrophoresis and bears the same apparent mo-
lecular weight as human synoviocyte lubricin [5].
Expression of lubricin sub-domains
cDNA from the human chondrosarcoma cell line SW1353 (ATCC, Manassas, VA) was used as
template to PCR amplify lubricin (PRG4) coding sequence for sub-cloning into an expression
vector that includes a signal peptide and a hemaglutinin (HA) epitope tag (YPYDVPDYA). Ex-
pression constructs included lubricin amino acid residues 26–278 (N), 281–857 (Mu1), 281–
627 (Mu1a), 281–377 (Mu1b), 629–857 (Mu1c), 857–1140 (Mu2), and 1141–1404 (C). Because
polypeptide Mu1b is small, human IgG-Fc coding sequence was added 3’ and in-frame with
the Mu1b fragment (Mu1b-Fc). The Fc expression construct, encodes a signal peptide followed
by an HA epitope tag and a human IgG-Fc domain using pcDNA3. To make the T-Fc expres-
sion construct, DNA encoding an octapeptide motif (KEPAPTTT) was introduced into the Fc
expression construct between the HA epitope tag and the IgG-Fc domain. Variants of the T-Fc
recombinant protein were generated by site-directed mutagenesis using a Quickchange kit
(Stratagene, La Jolla, CA).
To express recombinant protein, HEK-293T cells were cultured in DMEM with 10% fetal
bovine serum (FBS) at 37°C with 5% CO2, then transfected using serum free DMEM and Lipo-
fectamine Plus (Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. Serum-free
conditioned medium containing recombinant proteins was collected 48 hr after transfection.
Enzymatic deglycosylation of native and recombinant lubricin
Five μg of purified human lubricin was diluted in 100 μl reaction buffer (50 mM NaHPO3, pH
7.2, 0.01% w/v BSA) and treated with 80 mU of neuraminidase (ProZyme, Hayward, CA) and/
or 4 mU of O-glycosidase (Roche, Germany) at 37°C overnight. The digests were mixed with
100 μl of 2X SDS-PAGE loading buffer containing 2% v/v BME and boiled for 5 min. Two μl
were then electrophoresed in 4–20% gradient gels (Bio-Rad, Hercules, CA) and transferred to
Immobilon P-PVDF (Millipore, Bedford, MA).
Twenty μl of serum-free conditioned medium from HEK-293T cells containing rhPRG4
were treated with 30 mU of neuraminidase and/or 2 mU of O-glycosidase in a 50 μl reaction at
37°C overnight. The digested samples were then mixed with 50 μl of 2X SDS-PAGE loading
buffer and boiled for 5 min. Five μl of sample was electrophoresed and transferred to PVDF.
Immunodetection of lubricin onWestern blots
For synovial fluid samples: Following SDS-PAGE electrophoresis and transfer to Immobilon
P-PVDF, the membranes were incubated in TBS (20mM Tris and 150mMNaCl, PH 7.5)
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containing 5% w/v non-fat dried milk for 2 hr at 4°C. Following 3 washes in TBST (TBS with
0.01% w/v Tween 20), one of the mAbs (1:5000 dilution in TBST) or a polyclonal antibody
J108N [14] (1:2000 dilution in TBST) was incubated with the membrane for 16 to 20 hr at 4°C.
Following 3 washes in TBST, the membranes were incubated with horseradish peroxidase
(HRP) conjugated secondary antibodies (either goat anti-mouse IgG, goat anti-mouse IgG-Fab
specific, goat anti-rabbit IgG, or HRP-streptavidin, Pierce, Rockford, IL) at 1:5000 dilution.
Following 3 washes in TBST, immunoreactive bands were detected by chemiluminescence
using the ECL Plus Western Blotting detection kit (GE Healthcare, Buckinghamshire, UK).
The chemiluminescence signal was then captured with BioMax film (Kodak, Rochester, NY).
For purified mucin samples: Bovine submaxillary mucin and porcine gastric mucin (both
from Sigma-Aldrich, St. Louis, MO) were dissolved in PBS. Following SDS-PAGE electropho-
resis on a 4–12% polyacrylamide gels at 200 V for 1 hr and transferred at 24V to nitrocellulose
for 1 hr, membranes were incubated in PBST (10 mM KH2PO4, 0.15 M NaCl, 30 mM Na2
HPO47H2O, pH 7.4, with 0.05% w/v Tween 20) containing 5% w/v non-fat dried milk for 1 hr
at room temperature (RT), washed 3 times with PBST and incubated overnight at 4°C with of
the mAbs in PBST containing 5% w/v bovine serum albumin (BSA). Membranes were then
washed 3 times in PBST and incubated with secondary goat anti-mouse-IRdye-800 (0.1μl/ml)
at RT for 1 hr. Immunoreactive bands were then detected via Odyssey Infrared Imager Scanner
(Biosciences, LI-COR Inc.).
Competition ELISA assay
Individual wells in polystyrene 96-well plates (Corning Incorporated, Corning, NY) were coat-
ed using 100 μl of purified human lubricin [7] in PBS (10 μg/ml) at 4°C overnight. Wells were
then rinsed 3 times with PBS and blocked with 200 μl 5% (w/v) BSA in PBST at RT for 2 hr.
Serial dilutions of purified human lubricin (0–2 μg/ml) and purified rhPRG4 (0–100 μg/ml)
and dilutions of human synovial fluid, human serum and plasma were made using PBS. For
the assays reported in this study, 1:500 dilutions of synovial fluid and 1:50 dilutions of serum
or plasma were used. Fifty μl of standard or 50 μl of sample were added to ELISA plate wells
followed by 50 μl of biotin-conjugated mAb-7h12 (0.1 μg/ml in PBS) and incubated at RT for
1 hr. Wells were then rinsed 3 times with PBST and mAB-7h12 binding was detected by adding
100 μl of horseradish peroxidase conjugated Streptavidin (Pierce, Rockford, IL), diluted 1:1000
in PBS for 1 hr at RT, rinsing the wells 5 times with PBST, and developing with a horseradish
peroxidase substrate kit (Bio-Rad, Hercules, CA) using 100 μl tetramethyl benzidine (TMB). A
dark blue color was developed after 5–10 min, which was then stopped using 100 μl of 1N
H2SO4. OD415 nm readings were obtained using a plate reader. A standard curve was obtained
for each competition ELISA experiment. Lubricin concentrations in the test samples were de-
termined by comparing the OD415 nm readings of the samples with that experiment’s standard
curve. In the case of the rhPRG4 competition ELISA, which was documented by digital photog-
raphy, the substrate was ABTS Solution (Life Technologies, Grand Island, NY) and was quanti-
tated by OD450 nm.
Immunoprecipitation of lubricin from synovial fluid and blood
Biotin labeled mAb-7h12 (4 μg) was mixed with an 80 μl slurry of Streptavidin agarose beads
(Pierce, Rockford, IL) in a total of 1 ml PBS-T buffer (PBS with 0.1% Tween-20) and then agi-
tated at RT for 30 min followed by 2 washes with the PBS-T buffer. Beads were then re-sus-
pended in a total volume of 1 ml PBS-T buffer that included 100 μl plasma or serum, 5 μl
synovial fluid, or 0.5 μg purified human or bovine lubricin) and again agitated for 1 hr at RT.
After washing 5x with 1 ml PBS-T, the antibody-bound protein was eluted with 150 μl glycine-
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HCl (100 mM, pH 3.0) for 10 min. The supernatants were neutralized with 15 μl 1M Tris-HCl
(pH 8.5), boiled with 2x SDS-PAGE loading buffer, and subjected to gel electrophoresis fol-
lowed by Western blot analysis.
Immunohistochemical detection of lubricin in human tissues
Six μm sections were prepared from formalin fixed paraffin embedded human synovial tissue
samples from individuals without joint disease as well as from those with degenerative arthritis
and CACP. Sections were deparaffinized in xylene, rehydrated, and antigen retrieval was per-
formed in citrate buffer (pH 6) for 4 min at 125°C in a pressure cooker. Endogenous tissue per-
oxidase activity was quenched with 3% sodium hydroxide for 10 minutes and, following
washes in PBS, nonspecific antibody binding was blocked with 1.5% blocking serum (Sigma-
Aldrich). Antibody incubation and detection was performed using the VectaStain Elite Mouse
IgG ABC kit (Vector Laboratories, Burlingame, CA) according to the manufacturer’s recom-
mended protocol with appropriate controls. The antibody mAb-7h12 was used at a 1:400 dilu-
tion. Detection of the avidin/biotin/peroxidase-conjugated secondary antibody was performed
using DAB FastTabs substrate (Sigma-Aldrich) for 5 minutes, followed by counterstaining
with hematoxylin or hematoxylin and eosin. Slides were dehydrated and mounted for light
microscopic analysis.
Results
Generation of anti-lubricin monoclonal antibodies
Using direct ELISA, we screened >100 hybridomas derived from lubricin immunized Prg4-/-
mice for anti-lubricin antibodies. The use of Prg4-/- mice enabled us to generate mAbs that
react with lubricin from multiple mammalian species, including human, cow, pig, goat, dog,
and rat. Five hybridomas 7h12, 9g3, 5c11, 8e3 and 6a8 were recovered. The mAbs produced by
these hybridomas were all IgG class.
By Western blot, each mAb detected lubricin in 1 μl of synovial fluid from humans and sev-
eral other mammalian species (Fig. 1A). The specificity for lubricin was demonstrated by the
lack of immunoreactivity against synovial fluid from patients with CACP, who genetically lack
this protein (Fig. 1A). The mAbs exhibited no cross reactivity to μg amounts of bovine and por-
cine mucins in Western blots (Fig. 1B).
The mAbs recognize an O-linked oligosaccharide-containing
octapeptide epitope
To identify the epitope recognized by the mAbs we tested each antibody against subdomains of
human lubricin (Fig. 2). The antibodies recognized the first mucin-like domain (Mu1). They
did not detect the second mucin-like domain (Mu2), the amino-terminal globular domain (N),
or the carboxyl-terminal PEX domain (C). Because Mu1 is enriched with an octapeptide motif
(KEPAPTTT) that is present ~ 20 times in humans, we tested whether this peptide motif con-
stitutes the epitope for the mAbs. We expressed a recombinant protein (T-Fc) that contains a
single copy of this octapeptide motif in mammalian cells and confirmed that it contains the re-
active epitope for all mAbs (Figs. 2 and 3A). Since the octapeptide motif is partially degenerate
in human and other mammalian lubricins, we altered amino acid residues within the motif to
fully define the epitope (Fig. 3B). We found that the consensus peptide motif recognized by
these mAbs is K-E/A-P-A-P-T-T-T/A/P (Fig. 3B).
Threonine residues are sites of O-linked glycosylation in mucins and mucin-like proteins.
Fc-fused seven-peptide KEPAPTT and octapeptide KEPAPTAT recombinant proteins
Immunodetection of Lubricin
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migrated faster than other recombinant octapeptides (Fig. 3B) and were not detected by all
mAb’s (Fig. 3). This led us to hypothesize that KEPAPTT and KEPAPTAT were not glycosy-
lated and that O-linked glycosylation (Fig. 3B) is required for recognition by several mAbs. We
tested this by enzymatically digesting O-linked oligosaccharides from purified human lubricin
and recombinant protein (Fig. 3A). Removal of oligosaccharides reduced lubricin’s molecular
weight as demonstrated by immunoblotting (data not shown) with a polyclonal anti-lubricin
antibody J108N that detects a polypeptide motif in the protein’s amino-terminal domain (14).
Digestion with neuraminidase and O-glycosidase abolished immunoreactivity for mAb-7h12
and mAb-5c11, and reduced mAb-9g3 and mAb-6a8 immunoreactivity (Fig. 3A). Interesting-
ly, T-Fc digested by neuraminidase alone had an increased immunoreactivity to mAb-7h12,
mAb-5c11, and mAb-6a8 (Fig. 3A), and purified lubricin digested with neuraminidase also
showed this increase (data not shown), suggesting sialic acid residues decrease or block these
mAbs’ epitope. Bacterially expressed T-Fc and Mu1 were not immunodetectable with mAb-
7h12 (data not shown), which is also consistent with this and other antibodies detecting a com-
bined peptide and O-linked glycosylated epitope. Changes in gel mobility of the glycosidase di-
gested recombinant O-linked epitope in these experiments can be attributed to sialic acid
removal (Fig. 3C).
Fig 1. Western blots probed with anti-lubricin mousemonoclonal antibodies (mAbs) 9g3, 7h12, 5c11,
6a8, and 8e3 detect lubricin in synovial fluid but do not detect other mucins. (A) Five μg of human
lubricin purified from synovial fluid (PHL), and 1 μl of synovial fluid recovered from patients with osteoarthritis
(OA), CACP, or from bovine, porcine, goat, dog, rat and guinea pig were electrophoresed under reducing
conditions on 4–20% SDS-PAGE gradient gels, transferred to PVDF, and immunodetected using the biotin
labeled mAbs. Note that the mAbs detect protein in the synovial fluid from patients with OA and from other
species, but not from the patient with CACP, who is genetically deficient for lubricin. (B) 0.7 μg of Purified
human lubricin (PHL), porcine gastric mucin (PM) and bovine submaxillary mucin (BSM) were
electrophoresed under non-reducing conditions on 4–12% SDS-PAGE gradient gels, transferred to
nitrocellulose and immunodetected using the mAbs. For mAb-8e3, 1.4 μg of PHL was loaded. Note that anti-
lubricin mAbs did not cross react with BSM or PM.
doi:10.1371/journal.pone.0116237.g001
Immunodetection of Lubricin
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A competition ELISA using mAb-7h12 measures lubricin in human
serum, plasma, and synovial fluid
To determine whether lubricin in other body tissues originates predominantly from synovial
joints, we developed a competition ELISA and measured lubricin epitopes in urine, serum, and
plasma. We validated the competition ELISA using known amounts of purified human lubricin
Fig 2. ThemAbs detect an octapeptide motif present in the first mucin-like domain of human lubricin.
Different domains of lubricin (depicted in the top panel beneath a schematic of the protein and its 12 coding
exons) were cloned into a mammalian expression construct downstream of a signal peptide sequence and a
Hemaglutinin epitope-tag (HA) sequence. Domain Mu1b was also fused to a human IgG-Fc fragment (Mu1b-
Fc). An octapeptide motif (KEPAPTTT), which occurs multiple times within the first mucin-like domain (Mu1),
was also fused to the IgG-Fc fragment (T-Fc). These constructs were transiently transfected into 293T cells.
Serum-free conditioned media were collected and subjected to SDS-PAGE on 4–20% gradient gels. Anti-HA
antibody detected all recombinant proteins in the media (HA), although weak immunodetectable bands
occurred for Mu1a and Mu1c. Monoclonal antibodies 9g3, 7h12, 5c11 and 6a8 detected the secreted first
mucin domain Mu1, Mu1a and Mu1c, but not Mu1b or the second mucin domain Mu2. Mu1b is the first 98 AA
of the first mucin domain and does not contain KEPAPTTT; instead it has “KEPTPTT” and other “ETTT”-
containing repeats. The only peptide motifs that Mu1a and Mu1c share is: “KEPAPTTP”. Antibodies 9g3,
7h12 and 6a8 also strongly recognized the KEPAPTTT containing recombinant protein (T-Fc), while 5c11
weakly interacted with T-Fc. Horseradish peroxidase (HRP) conjugated anti-mouse IgG, which was used as
secondary antibody to detect 9g3, showed weak cross reactivity to human IgG-Fc. HRP-conjugated
Streptavidin was used as a secondary antibody to detect biotin-labeled 7h12, 5c11 and 6a8, and showed no
cross-reactivity by itself (data not shown).
doi:10.1371/journal.pone.0116237.g002
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Fig 3. ThemAbs recognize an epitope that contains an O-linked glycanmodification of the octapeptide K-E/A-P-A-P-T-T-T/A/P. Serum-free
conditioned media from 293T cells expressing T-Fc (i.e., KEPAPTTT) recombinant protein or variants of this octapeptide motif were resolved on reducing
SDS-PAGE gel and immunodetected with the mAbs. (A) Recombinant T-Fc immunodetected using antibodies indicated in each panel. Removal of O-linked
glycans by enzymatic digestion with neuraminidase and O-glycosidase caused loss or attenuated recognition by all mAbs, except anti-HA antibody.
Immunodetection of Lubricin
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(Fig. 4). As expected, there was an inverse correlation between the amount of lubricin that was
pre-incubated with mAb-7h12 and the degree of antibody binding to lubricin-coated ELISA
wells (Fig. 4A). A reproducible correlation occurred when the concentration of lubricin that
was pre-incubated with antibody ranged from 0–2 μg/ml (Fig. 4B). When testing biologic spec-
imens that contain lubricin as a positive control we used dilutions of synovial fluid from pa-
tients with OA and RA. As a negative control, we used dilutions of synovial fluid from patients
with CACP (Fig. 4C). The competition ELISA could measure lubricin in 1:500 dilutions of RA
and OA synovial fluid and did not detect lubricin in CACP synovial fluid. The competition
ELISA could also measure lubricin in 1:50 dilutions of serum and plasma (Fig. 4C), but not in
urine (data not shown). As expected, plasma from individuals with CACP (CA697–1, CA698–
1, CA698–2) lacked lubricin, while plasma and serum from unaffected relatives (CA697–2,
CA698–4, CA698–5) and unrelated controls (OT701–1, OT702–1) had quantifiable amounts
of lubricin.
There was also an inverse and reproducible correlation between the amount of rhPRG4 that
was preincubated with each of the individual mAbs and the degree of antibody binding to a
rhPRG4 coated ELISA well (Fig. 4D). For most mAbs a quasi-linear correlation was observed
when the concentration of rhPRG4 pre-incubated with antibody ranged from 0–2 μg/ml;
mAb-9g3 had a quasilinear correlation when rhPRG4 ranged from 0–20 μg/ml.
Having found lubricin epitopes in serum and plasma, we next examined their characteris-
tics. Specifically, we wanted to know whether they were within an intact or degraded mucin-
like domain. After separating serum proteins by size exclusion, the immunodetectable epitopes
remained in the large molecular weight (>100 kDa) fraction, suggesting that the mucin-like
domain in serum is intact (data not shown). We obtained the same result when synovial fluid
proteins were similarly fractionated (data not shown). Taken together, these results suggest
that the immunodetectable lubricin in serum does not represent degradation products from sy-
novial fluid. Further support for this conclusion derives from the comparison of serum lubricin
levels in 30 patients with active RA and their age/sex-matched controls (Table 1), which found
no significant difference.
The Pearson correlation coefficients between serum lubricin level and age were both 0.08 in
cases and controls. The correlation between serum lubricin level and C-reactive protein level in
cases was -0.31. No significant difference in mean serum lubricin levels between cases and con-
trols was observed using a two-tailed, paired, student t-test (p = 0.07).
We also immunoprecipitated (IP) lubricin from blood and synovial fluid with mAb-7h12
and then probed the precipitated protein with mAb-7h12 and polyclonal Ab-J108N; the latter
polyclonal antibody detects an epitope within the amino-terminal domain of all PRG4 splice-
forms [23]. As expected, no lubricin protein could be immunoprecipitated from plasma or sy-
novial fluid from patients with CACP (Fig. 5). If lubricin in blood originated in the synovial
fluid and represented a degradation product, we expected it to lack the amino-terminal
Interestingly, all mAbs showed significantly increased immunoreactivity to the recombinant protein treated with neuraminidase alone, suggesting sialic acid
modifications that usually occur at sugar chain termini interfere with epitope-antibody interactions. (B) Recombinant HA-KEPAPTTT-Fc (T-Fc) and HA-IgG-
Fc (Fc) proteins were treated by neuraminidase and/or O-glycosidase and immunodetected using anti-human IgG-Fc. Note sugar modification on the
KEPAPTTT peptide, but not on the Fc fragment, is responsible for changes in polypeptide mobility upon deglycosylation. (C) Recombinant octapeptides
fused downstream of HA and upstream of IgG-Fc immunodetected using antibodies indicated in each panel. Anti-HA antibody showed that all mutant
recombinant proteins were expressed. Recombinant protein HA-KEPAPTTT-Fc (1) was immunodetected by all monoclonal antibodies. These antibodies did
not detect the variant forms of the recombinant protein: HA-KEPAPTAT-Fc (2); HA-KEPAATTT-Fc (3); HA-KEPAPTT-Fc (4); HA-PAPTTT-FC (5). Note that
the anti-mouse IgG, used as secondary antibody for mAb-9g3, showed strong cross-reactivity with the human IgG-Fc present in all recombinant proteins.
HRP-conjugated Streptavidin was used as a secondary antibody to detect biotin-labeled mAbs 7h12, 5c11 and 6a8, and showed no background by itself
(data not shown). (D) Schematic depicting the peptide and O-linked glycosylation motifs that occur commonly in the mucin-like domain of human lubricin.
Sialylated and non-sialylated O-linked oligosaccharides can be added to the Threonine (T) residues; two potential oligosaccharides (sialylated and non-
sialylated) are indicated and their relative affinities to the mAbs are indicated by the arrow weights.
doi:10.1371/journal.pone.0116237.g003
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domain. Surprisingly, we obtained the opposite result. That is, the fraction of lubricin mole-
cules having an intact amino-terminal domain epitope is larger in blood than in synovial fluid
(Fig. 5).
Lubricin is immunodetected in healthy synovium and synovium from
patients with acquired joint disease, but not in synovium from patients
with CACP
We performed immunohistochemistry using mAb-7h12 on paraffin embedded formalin fixed
synovial tissue sections from patients with osteoarthritis and pigmented villonodular synovitis
and on synovium, obtained at autopsy, from an individual without joint disease. In addition,
we studied synovial biopsy samples from two unrelated patients with CACP. In contrast to
finding immunodetectable lubricin in the synovium of a healthy joint or a joint with an ac-
quired disease, we did not detect lubricin in synovium from a CACP joint (Fig. 6).
Fig 4. mAb-7h12 canmeasure lubricin in human plasma, serum, and synovial fluid by competition ELISA. (A) Photograph showing the result of a
competition ELISA performed in triplicate. Biotin-labeled mAb-7h12 (0.2 μg/ml) was pre-incubated with purified lubricin (the concentrations of purified lubricin
are indicated on top of each column) and added to lubricin-coated wells. After several washes, the mAb bound to the lubricin-coated wells, was detected
colorimetrically using horseradish peroxidase (HRP) conjugated to streptavidin. Note when antibody is not pre-incubated with lubricin (0 μg/ml), all antibody
binds to the pre-coated wells and the HRP-streptavidin detection of bound antibody turns these wells dark blue. In contrast, pre-incubating the antibody with
increasing amounts of purified lubricin reduces antibody binding to the wells and there is less color formation by HRP-streptavidin. (B) Standard curve
derived from the O.D. 415 nm values for the competition ELISA shown in panel A. The x-axis indicates the concentration of lubricin (μg/ml) that was pre-
incubated with the antibody; the y-axis indicates the average difference in O.D. reading compared to the 0 μg/ml lubricin control. (C) Photograph showing the
result of a competition ELISA performed in duplicate (individual rows). Biotin-labeled mAb-7h12 (0.2 μg/ml) was pre-incubated with 1:50 dilutions of human
plasma or serum, or 1:50,000 dilutions of human synovial fluid. The plasma samples are from patients with CACP (CA697–1, CA698–1, CA698–2) and their
unaffected family members (CA697–2, CA698–4, CA698–5). The serum samples are from healthy controls (OT701–1; OT702–1). The synovial fluid samples
are from patients with OA, RA, or CACP (CA). Note that plasma and synovial fluid from patients with CACP do not reduce antibody binding to lubricin-coated
wells as indicated by the dark blue color, whereas plasma, serum, or synovial fluid from unaffected individuals does reduce antibody binding to the lubricin-
coated wells. Based upon the measured O.D. values for these samples (data not shown), no detectable lubricin is present in serum and synovial fluid from
patients with CACP, whereas ~ 200 μg/ml is present in the RA and OA synovial fluid samples and ~ 0.2 μg/ml is present in the plasma and serum samples
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Discussion
The precocious joint failure that occurs in patients with CACP, a genetic deficiency of lubricin,
reveals the importance of this protein for protecting joints [12]. Acquired deficiency of lubricin,
as can occur following trauma, infection, or inflammation may also hasten the onset or pro-
gression of joint failure, where loss of chondrocytes appears to be linked to excessive friction at
the joint surface [18]. Although lubricin is an abundant protein in synovial fluid, its synthesis,
post-translational modification, localization, and degradation remain incompletely under-
stood. We have generated and characterized sensitive and specific mAbs against human lubri-
cin to further our understanding of these processes.
These antibodies detect a combined oligosaccharide/peptide epitope that occurs multiple
times within the protein’s first mucin-like domain. The presence of multiple copies of this epi-
tope accounts for the antibodies’ sensitivity, while the uniqueness of the epitope sequence ex-
plains the antibodies’ specificity. Interestingly, O-linked oligosaccharides are part of the
epitope, yet the epitope may be partially blocked when these oligosaccharides are capped by
Table 1. Serum lubricin levels in 30 individuals with active rheumatoid arthritis (RA) and 30 age- and sex- matched controls (Con).
RA ID Sex Age CRP Lub (ng/μl) Con ID Sex Age Lub (ng/μl)
00500 F 59 29.7 1.08 DL0291 F 59 1.06
00264 F 55 31.4 1.00 DL0026 F 55 0.65
00809 M 68 33.6 0.97 DL0440 M 68 0.79
00867 M 53 33.7 1.02 DL0014 M 53 0.86
00594 M 58 33.7 1.20 DL0024 M 58 0.97
00490 F 69 35.2 0.79 DL0067 F 69 0.74
00231 M 58 37.2 0.92 DL0090 M 58 1.02
00481 M 57 37.2 0.90 DL0227 M 57 1.15
00769 F 48 37.3 1.20 DL0074 F 48 0.64
00606 F 60 37.9 1.20 DL0160 F 60 1.29
00813 F 50 39.0 1.03 DL0071 F 50 1.00
00443 M 48 39.9 0.90 DL0012 M 48 0.90
00282 M 63 41.0 0.99 DL0017 M 63 0.70
00852 F 72 41.9 0.97 DL0664 F 73 1.24
00819 F 44 43.7 0.79 DL0101 F 44 1.00
00513 F 54 45.6 1.41 DL0202 F 54 0.70
00156 F 44 50.2 0.96 DL0129 F 44 1.20
00779 F 53 53.2 1.21 DL0128 F 53 0.67
00519 F 68 57.3 1.30 DL0773 F 68 0.95
00152 F 49 61.0 0.98 DL0295 F 49 0.85
00261 M 46 61.8 0.63 DL0056 M 46 0.86
00854 F 65 64.1 0.90 DL0033 F 65 0.95
00634 F 71 74.1 0.89 DL0739 F 70 0.73
00512 M 48 76.9 0.76 DL0057 M 48 0.54
00536 F 38 88.3 0.93 DL0413 F 38 0.82
00232 M 70 90.4 0.53 DL0016 M 70 0.72
00645 M 65 90.9 0.98 DL0032 M 65 0.95
00777 F 47 109 0.75 DL0047 F 47 0.82
00615 F 79 113 1.14 DL0692 F 79 0.82
00506 M 68 145 0.88 DL0479 M 68 1.03
doi:10.1371/journal.pone.0116237.t001
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sialic acid. The mAbs reported here detected lubricin in synovial fluid from multiple species,
but did so with differing sensitivity. This may be due to differences in the number of
KEPAPTTT repeats (e.g., humans have 26 repeats, mice have 7), the nature of the linked oligo-
saccharides, or the extent to which they are sialylated. Since glycosylation is essential to the
protein’s lubricating function [20], it may become valuable to employ antibodies, such as
mAb-7h12 and mAb-5c11, to determine whether the extent and nature of glycosylation change
during aging or as a consequence of disease [21].
The mAbs could detect lubricin in serum and plasma by competition ELISA. Previously, we
demonstrated absence of lubricin in synovial fluid from patients with CACP [23]. Here we
show that lubricin was undetectable in blood from several patients with CACP, but detectable
in their unaffected relatives and controls. Since most identified CACP disease-causing muta-
tions in PRG4 abolish lubricin production, the sensitivity of the competition ELISA as a diag-
nostic test for CACP should be high; however, other diagnostic strategies including sequencing
of PRG4, will be required for the minority of patients with CACP who have mutations that af-
fect lubricin function rather than production.
Because the epitopes of the mAbs were within the protein’s mucin domain we have been
able to gain insight into the mechanism by which lubricin is degraded within joints. In contrast
Fig 5. Immunoprecipitation of lubricin from human serum, plasma and synovial fluid. Biotin-labeled
mAb-7h12 was mixed with plasma samples from a patient with CACP (CA697–1) or his unaffected father
(CA697–2), serum samples from a patient with rheumatoid arthritis (RA) or an age- and sex-matched healthy
control (Control), synovial fluid samples from a patient with osteoarthritis (OA), rheumatoid arthritis (RA), or
CACP (CA), and with human (hLub-IP) and bovine (bLub-IP) lubricin that had been purified from synovial
fluid. Antibody was recovered using streptavidin beads and proteins co-precipitated with mAb-7h12 were
eluted, subjected to SDS-PAGE, transferred to PVDF, and immunodetected with mAb-7h12 (upper panel) or
polyclonal Ab-J108N (lower panel). Note mAb-7h12 immunoprecipitated lubricin from plasma and serum that
is also recognized by polyclonal antibody J108N. In contrast, lubricin immunoprecipitated from OA and RA
synovial fluid is not recognized by polyclonal antibody J108N. J108N also does not recognize
immunoprecipitated purified human lubricin (hLub-IP). The is no non-specific binding of lubricin to
streptavidin beads as demonstrated by the lack of immunodetectable protein when mAb-7h12 is not used in
the co-IP (no Ab control) of plasma from the unaffected CACP parent or synovial fluid from a patient with RA.
As positive controls for immunodetection purified human and bovine lubricin (hLub and bLub) were directly
subjected to SDS-PAGE for immunodetection.
doi:10.1371/journal.pone.0116237.g005
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the gastrointestinal and respiratory tracts, where mucins are degraded by glycosidases and pep-
tidases expressed by resident bacteria, synovial joints are sterile thereby precluding this mecha-
nism of degradation. We used a competition ELISA to compare the abundance of lubricin
epitopes in the serum of patients with active inflammatory joint disease to age- and sex-
matched controls and we found no difference. This suggests that the glycosylated KEPAPTTT
epitope in serum does not originate from synovial joints. Although this result does not preclude
other lubricin fragments in serum from originating in synovial fluid, it implies that degradation
of the mucin-like domain occurs intracellularly with little or no release of glycosylated oligo-
peptide. Further support for this conclusion derives from the failure to find small molecular
weight fragments from the mucin-like domain in synovial fluid.
Even though the mucin-like domain of lubricin is degraded intracellularly, it is clear that
other lubricin domains are subjected to extracellular degradation. For example, the polyclonal
Ab-J108N, detected full-length lubricin and degradation fragments containing the protein’s
amino-terminal globular domain in synovial fluid from patients with active RA [23]. Therefore,
comparing ratios of intact and degraded lubricin within synovial fluid may be useful in moni-
toring disease status. Interestingly, most lubricin molecules within synovial fluid do not contain
the epitope recognized by J108N, which differs from what we observed for blood. Whether this
difference represents a post-translational modification of the amino-terminal domain that
hides the epitope or cleavage of this domain from the remainder of the protein remains to
be determined.
Other antibodies have previously provided insight into lubricin biology. Monoclonal anti-
bodies (3-A-4 and 6-A-1) generated against the carboxyl-terminal globular domain of bovine
lubricin demonstrated lubricin expression by superficial zone chondrocytes and synoviocytes
[27], localization at cartilage [28] and meniscal [29] surfaces, and the compressive surfaces of
tendon [30]. Antibody 3-A-4 was also used to demonstrate the ability of lubricin in synovial
fluid to re-adhere to a cartilage surface that had been stripped of lubricin with 1.5 M NaCl [31].
However, neither antibody is able to immunodetect human lubricin. A polyclonal antibody,
06A10, generated against an unspecified truncated form of recombinant human lubricin was
used immunohistochemically to detect sheep lubricin [32]. This antibody was also used to
show that recombinant human lubricin, which had been reduced and alkylated, did not avidly
bind to the cartilage surface compared to non-reduced protein [32]. Several monoclonal anti-
bodies generated against lubricin (SZP) recovered from cultured human chondrocytes have
been used for immunohistochemistry, western blotting, and sandwich ELISA [33]. Although
the epitopes recognized by these antibodies were not reported, a surprising observation was the
Fig 6. Immunodetection of lubricin in synovial tissue. Photomicrographs of tissue sections from archival
human synovial biopsies from patients with osteoarthritis (A) or CACP (B). Sections had been incubated with
mAb-7h12 and detected with avidin/biotin/peroxidase. Note immunodetectable lubricin (brown-colored stain)
is concentrated along the surface of OA synovium, and not found in CACP synovium. The OA sample was
counterstained with hematoxylin & eosin and imaged at 1000X magnification. The CACP sample was
counterstained with eosin and imaged at 600X magnification.
doi:10.1371/journal.pone.0116237.g006
Immunodetection of Lubricin
PLOS ONE | DOI:10.1371/journal.pone.0116237 February 2, 2015 14 / 17
ability of one monoclonal antibody (S13.52) to recognize lubricin purified from human synovi-
al fluid but not from articular cartilage. Of even greater surprise was that this antibody detected
similar abundances for lubricin in serum and synovial fluid. This result is surprising since we
estimated the abundance of lubricin in serum at 0.2 μg/ml and in synovial fluid at 200 μg/ml
using mAb-7h12 and the competition ELISA (Fig. 4). Our quantification may not accurately
reflect protein abundance if the extent or type of lubricin O-linked glycosylation found in
serum differs from that found in synovial fluid. However, the studies that employed S13.52 and
S6.89 did not utilize serum and synovial fluid from patients with CACP as negative controls, so
cross reactivity with another serum protein may explain their result. Monoclonal antibody
S6.89 has been used in a number of other species recognizing cow, rabbit, guinea pig [33], and
dog [34]. Of the present monoclonal antibodies we report here, mAb-9g3 has been used immu-
nohistochemically in rats [35] and mAb-5c11 in cow [6].
In conclusion, we have produced a set of sensitive mAbs that are specific to a repetitive, gly-
cosylated, octapeptide motif of human lubricin, and used one of them to improve the laborato-
ry diagnosis of a Mendelian genetic skeletal disease CACP, to distinguish degradation of
lubricin that occurs intracellularly from that which occurs extracellularly, and to begin delin-
eating how monitoring the extracellular degradation of lubricin can be used to assess joint
health. Investigators studying other animal models of joint disease may find these mAbs useful,
since they detect lubricin from several species.
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